Publications en collaboration avec des chercheurs de Hospital Universitario de Cruces (27)

2024

  1. Damage measured by Damage Index for Antiphospholipid Syndrome (DIAPS) in antiphospholipid antibody-positive patients included in the APS ACTION registry

    Rheumatology (United Kingdom), Vol. 63, Núm. 3, pp. 772-779

2023

  1. Anti–Neutrophil Extracellular Trap Antibodies in Antiphospholipid Antibody–Positive Patients: Results From the Antiphospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking Clinical Database and Repository

    Arthritis and Rheumatology, Vol. 75, Núm. 8, pp. 1407-1414

2022

  1. Characteristics of Patients With Antiphospholipid Antibody Positivity in the APS ACTION International Clinical Database and Repository

    Arthritis Care and Research, Vol. 74, Núm. 2, pp. 324-335

  2. Pregnancy outcomes in antiphospholipid antibody positive patients: prospective results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository ( € Registry')

    Lupus Science and Medicine, Vol. 9, Núm. 1

2021

  1. Antiphospholipid antibody profile stability over time: Prospective results from the APS ACTION clinical database and repository

    Journal of Rheumatology, Vol. 48, Núm. 4, pp. 541-547

  2. Clinical and laboratory characteristics of Brazilian versus non-Brazilian primary antiphospholipid syndrome patients in AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) clinical database and repository

    Advances in Rheumatology, Vol. 61, Núm. 1

2020

  1. Cluster analysis for the identification of clinical phenotypes among antiphospholipid antibody-positive patients from the APS ACTION Registry

    Lupus, Vol. 29, Núm. 11, pp. 1353-1363

  2. Second week methyl-prednisolone pulses improve prognosis in patients with severe coronavirus disease 2019 pneumonia: An observational comparative study using routine care data

    PLoS ONE, Vol. 15, Núm. 9 September

2019

  1. Comparison of real world and core laboratory lupus anticoagulant results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) clinical database and repository

    Journal of Thrombosis and Haemostasis, Vol. 17, Núm. 12, pp. 2069-2080

  2. Factors associated with first thrombosis in patients presenting with obstetric antiphospholipid syndrome (APS) in the APS Alliance for Clinical Trials and International Networking Clinical Database and Repository: a retrospective study

    BJOG: An International Journal of Obstetrics and Gynaecology, Vol. 126, Núm. 5, pp. 656-661

  3. The Impact of Systemic Lupus Erythematosus on the Clinical Phenotype of Antiphospholipid Antibody–Positive Patients: Results From the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Clinical Database and Repository

    Arthritis Care and Research, Vol. 71, Núm. 1, pp. 134-141

  4. The comparison of real world and core laboratory antiphospholipid antibody ELISA results from antiphospholipid syndrome alliance for clinical trials & international networking (APS ACTION) clinical database and repository analysis

    Thrombosis Research, Vol. 175, pp. 32-36

2018

  1. Combined mepacrine–hydroxychloroquine treatment in patients with systemic lupus erythematosus and refractory cutaneous and articular activity

    Lupus, Vol. 27, Núm. 10, pp. 1718-1722

  2. Comment on: The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults

    Rheumatology (Oxford, England)

  3. Glucocorticoids and antimalarials in systemic lupus erythematosus: an update and future directions

    Current opinion in rheumatology, Vol. 30, Núm. 5, pp. 482-489

  4. Restrictive Use of Oral Glucocorticoids in Systemic Lupus Erythematosus and Prevention of Damage Without Worsening Long-Term Disease Control: An Observational Study

    Arthritis Care and Research, Vol. 70, Núm. 4, pp. 582-591

2017

  1. A Pilot Study of the Usefulness of a Single Olanzapine Plasma Concentration as an Indicator of Early Drug Effect in a Small Sample of First-Episode Psychosis Patients

    Journal of Clinical Psychopharmacology, Vol. 37, Núm. 5, pp. 569-577

  2. Repeated pulses of methyl-prednisolone with reduced doses of prednisone improve the outcome of class III, IV and V lupus nephritis: An observational comparative study of the Lupus-Cruces and lupus-Bordeaux cohorts

    Autoimmunity Reviews, Vol. 16, Núm. 8, pp. 826-832

2016

  1. Prevention of Recurrent Thrombosis in Antiphospholipid Syndrome: Different from the General Population?

    Current Rheumatology Reports, Vol. 18, Núm. 5

  2. Rituximab-refractory lupus nephritis successfully treated with belimumab

    Clinical and Experimental Rheumatology